Apr 11 |
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTACĀ® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer
|
Apr 9 |
Is Arvinas (ARVN) Stock a Solid Choice Right Now?
|
Mar 19 |
Arvinas gets new chief medical officer
|
Mar 18 |
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer
|
Mar 4 |
Arvinas to Participate in Upcoming Investor Conferences
|
Mar 3 |
Arvinas: Behind The Huge Rally
|
Mar 1 |
Arvinas, Inc. (NASDAQ:ARVN) Just Reported Yearly Earnings: Have Analysts Changed Their Mind On The Stock?
|
Feb 28 |
Is a Surprise Coming for Arvinas (ARVN) This Earnings Season?
|
Feb 27 |
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates
|
Feb 27 |
Arvinas GAAP EPS of -$2.53 misses by $1.38, revenue of -$43.1M misses by $92.4M
|